Journal of Neuroscience
June 19, 2020
Lilian Weber, Andreea O. Diaconescu, Christoph Mathys et al.
82 citations
The auditory mismatch negativity (MMN) is significantly reduced in schizophrenia. Notably, a similar MMN reduction can be achieved with NMDA receptor (NMDAR) antagonists. Both phenomena have been interpreted as reflecting an impairment of predictive coding or, more generally, the "Bayesian brain" notion that the brain continuously updates a hierarchical model to infer the causes of its sensory...
Sri Lanka Journal of Psychiatry
June 18, 2020
Nisha Ravindran, Arun Ravindran
A significant proportion of patients with major depressive disorder are refractory to approved interventions. The first report of significant and rapid benefit of intravenous (IV) ketamine for treatment resistant depression (TRD) appeared in 2000. Since then, there have been multiple reports on the efficacy and tolerability of ketamine formulations for TRD, in particular for single-dose IV...
General Psychiatry
June 18, 2020
Xiao-Mei Li, Zhan-Ming Shi, Hua Hu et al.
13 citations
Background The use of ketamine in electroconvulsive therapy (ECT) has been examined in the treatment of major depressive disorder (MDD); however, there has been no systematic review and meta-analysis of related randomised controlled trials (RCTs).Aim To examine the efficacy and safety of ketamine augmentation of ECT in MDD treatment.Methods Two reviewers searched Chinese (China National...
Molecular Brain
June 16, 2020
L. Aleksandrova, Y. Wang, A. Phillips
87 citations
Accumulating evidence implicates dysregulation of hippocampal synaptic plasticity in the pathophysiology of depression. However, the effects of ketamine on synaptic plasticity and their contribution to its mechanism of action as an antidepressant, are still unclear. We investigated ketamine’s effects on in vivo dorsal hippocampal (dHPC) synaptic plasticity and their role in mediating aspects of...
Expert Opinion on Drug Safety
June 15, 2020
Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al.
50 citations
ABSTRACT Objectives Rigorous clinical trials suggest ketamine is safe and well-tolerated in patients with treatment-resistant depression (TRD). There is a paucity of data on the safety and tolerability of ketamine in community-based clinics treating patients with TRD. Methods Retrospective data was analyzed from 203 patients with TRD who received repeat-dose IV ketamine. Safety was...
Brain Research
June 13, 2020
Katsuhiro Aikawa, Takayuki Yoshida, Yu Ohmura et al.
Juvenile stress, like that caused by childhood maltreatment, is a significant risk factor for psychiatric disorders such as depression later in life. Recently, the antidepressant effect of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist, has been widely investigated. However, little is known regarding its efficacy against depressive-like alterations caused by juvenile...
Scientific Reports
June 11, 2020
A U Nicol, A J Morton
Ketamine is a valuable anaesthetic and analgesic that in recent years has gained notoriety as a recreational drug. Recently, ketamine has also been proposed as a novel treatment for depression and post-traumatic stress disorder. Beyond its anaesthetic actions, however, the effects of ketamine on brain activity have rarely been probed. Here we examined the cortical electroencephalography (EEG)...
Frontiers in Psychiatry
June 3, 2020
Alina Wilkowska, Łukasz P. Szałach, Jakub Słupski et al.
9 citations
There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited. This case presents bipolar I disorder patient with treatment resistant depressive episode experiencing a switch to manic episode with mixed features shortly after receiving eight...
BMC Psychiatry
June 2, 2020
J. Phillips, N. Jaworska, Elizabeth Kamler et al.
22 citations
Background Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing...
Journal of Affective Disorders
June 1, 2020
A. Camargo, A. P. Dalmagro, A. Zeni et al.
Background Augmentation therapies may be effective strategies to potentiate the ketamine's actions with lower potential for knock-on effects. Thus, this study investigated the ability of combined administration of guanosine plus ketamine to elicit an antidepressant-like effect associated with mTOR pathway modulation. The ability of this combined administration to exert an antidepressant-like...